T-Lymphocytes, Regulatory

"T-Lymphocytes, Regulatory" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.

Descriptor ID	D050378
MeSH Number(s)	A11.118.637.555.567.550.500.700 A11.118.637.555.567.569.200.700 A11.118.637.555.567.569.500.700 A15.145.229.637.555.567.550.500.700 A15.145.229.637.555.567.569.200.700 A15.145.229.637.555.567.569.500.700 A15.382.490.555.567.550.500.700 A15.382.490.555.567.569.200.700 A15.382.490.555.567.569.500.700
Concept/Terms	T-Lymphocytes, Regulatory T-Lymphocytes, Regulatory T Lymphocytes, Regulatory Regulatory T-Lymphocytes Regulatory T Lymphocytes Regulatory T-Lymphocyte T-Lymphocyte, Regulatory Regulatory T-Cells Regulatory T Cells T-Cells, Regulatory T Cells, Regulatory Treg Cells Cell, Treg Cells, Treg Treg Cell Th3 Cells Th3 Cells Cell, Th3 Cells, Th3 Th3 Cell Suppressor T-Lymphocytes, Naturally-Occurring Suppressor T-Lymphocytes, Naturally-Occurring Naturally-Occurring Suppressor T-Lymphocyte Naturally-Occurring Suppressor T-Lymphocytes Suppressor T Lymphocytes, Naturally Occurring Suppressor T-Lymphocyte, Naturally-Occurring Suppressor T-Cells, Naturally-Occurring Naturally-Occurring Suppressor T-Cell Naturally-Occurring Suppressor T-Cells Suppressor T Cells, Naturally Occurring Suppressor T-Cell, Naturally-Occurring T-Cell, Naturally-Occurring Suppressor T-Cells, Naturally-Occurring Suppressor Tr1 Cells Tr1 Cells Cell, Tr1 Cells, Tr1 Tr1 Cell

Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Regulatory".

Anatomy [A]
Cells [A11]
Blood Cells [A11.118]
Leukocytes [A11.118.637]
Leukocytes, Mononuclear [A11.118.637.555]
Lymphocytes [A11.118.637.555.567]
Lymphocyte Subsets [A11.118.637.555.567.550]
T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
T-Lymphocytes, Regulatory [A11.118.637.555.567.550.500.700]
T-Lymphocytes [A11.118.637.555.567.569]
CD4-Positive T-Lymphocytes [A11.118.637.555.567.569.200]
T-Lymphocytes, Regulatory [A11.118.637.555.567.569.200.700]
T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
T-Lymphocytes, Regulatory [A11.118.637.555.567.569.500.700]
Hemic and Immune Systems [A15]
Blood [A15.145]
Blood Cells [A15.145.229]
Leukocytes [A15.145.229.637]
Leukocytes, Mononuclear [A15.145.229.637.555]
Lymphocytes [A15.145.229.637.555.567]
Lymphocyte Subsets [A15.145.229.637.555.567.550]
T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
T-Lymphocytes, Regulatory [A15.145.229.637.555.567.550.500.700]
T-Lymphocytes [A15.145.229.637.555.567.569]
CD4-Positive T-Lymphocytes [A15.145.229.637.555.567.569.200]
T-Lymphocytes, Regulatory [A15.145.229.637.555.567.569.200.700]
T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
T-Lymphocytes, Regulatory [A15.145.229.637.555.567.569.500.700]
Immune System [A15.382]
Leukocytes [A15.382.490]
Leukocytes, Mononuclear [A15.382.490.555]
Lymphocytes [A15.382.490.555.567]
Lymphocyte Subsets [A15.382.490.555.567.550]
T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
T-Lymphocytes, Regulatory [A15.382.490.555.567.550.500.700]
T-Lymphocytes [A15.382.490.555.567.569]
CD4-Positive T-Lymphocytes [A15.382.490.555.567.569.200]
T-Lymphocytes, Regulatory [A15.382.490.555.567.569.200.700]
T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
T-Lymphocytes, Regulatory [A15.382.490.555.567.569.500.700]

Below are MeSH descriptors whose meaning is related to "T-Lymphocytes, Regulatory".

Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Regulatory".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "T-Lymphocytes, Regulatory" by people in this website by year, and whether "T-Lymphocytes, Regulatory" was a major or minor topic of these publications.

Bar chart showing 326 publications over 26 distinct years, with a maximum of 30 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	2	2	4
1992	2	3	5
1993	2	2	4
1994	1	0	1
1995	3	0	3
1996	1	0	1
1998	1	1	2
2001	0	1	1
2004	2	3	5
2005	4	0	4
2006	11	2	13
2007	14	5	19
2008	17	7	24
2009	11	7	18
2010	17	13	30
2011	15	8	23
2012	18	6	24
2013	17	6	23
2014	9	9	18
2015	8	9	17
2016	12	4	16
2017	11	5	16
2018	10	5	15
2019	12	11	23
2020	4	4	8
2021	4	5	9

Below are the most recent publications written about "T-Lymphocytes, Regulatory" by people in Profiles.

Anvari S, Watkin L, Rajapakshe K, Hassan O, Schuster K, Coarfa C, Davis CM. Memory and naïve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy. Clin Immunol. 2021 09; 230:108820.

View in: PubMed
Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 07 05; 218(7).

View in: PubMed
Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun. 2021 05 11; 12(1):2722.

View in: PubMed
Srinivasan J, Lancaster JN, Singarapu N, Hale LP, Ehrlich LIR, Richie ER. Age-Related Changes in Thymic Central Tolerance. Front Immunol. 2021; 12:676236.

View in: PubMed
Ali R, Patel S, Hussain T. Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia. Am J Physiol Renal Physiol. 2021 05 01; 320(5):F814-F825.

View in: PubMed
Muscarella AM, Aguirre S, Hao X, Waldvogel SM, Zhang XH. Exploiting bone niches: progression of disseminated tumor cells to metastasis. J Clin Invest. 2021 03 15; 131(6).

View in: PubMed
González-Navajas JM, Fan DD, Yang S, Yang FM, Lozano-Ruiz B, Shen L, Lee J. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. Front Immunol. 2021; 12:625783.

View in: PubMed
Anvari S, Schuster K, Grimbergen A, Davis CM, Makedonas G. Attenuation of GARP expression on regulatory T cells by protein transport inhibitors. J Immunol Methods. 2021 05; 492:112998.

View in: PubMed
Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021 02 05; 12(1):832.

View in: PubMed
Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432.

View in: PubMed

People

Explore

Similar Concepts

Top Journals